Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome
Prashant Pandya, Chaitanya Pant, Ryan Taylor, Olurinde Oni
DOI: 10.1136/jim-2016-000343 Published 24 March 2017
Prashant Pandya
1Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, USA
2Division of Gastroenterology, Hepatology and Motility, Department of Internal Medicine, Kansas University Medical Center, Kansas City, Kansas, USA
Chaitanya Pant
2Division of Gastroenterology, Hepatology and Motility, Department of Internal Medicine, Kansas University Medical Center, Kansas City, Kansas, USA
Ryan Taylor
2Division of Gastroenterology, Hepatology and Motility, Department of Internal Medicine, Kansas University Medical Center, Kansas City, Kansas, USA
Olurinde Oni
1Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, USA
Submit a Response to This Article
No eLetters have been published for this article.
Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome
Prashant Pandya, Chaitanya Pant, Ryan Taylor, Olurinde Oni
Journal of Investigative Medicine Apr 2017, 65 (4) 765-771; DOI: 10.1136/jim-2016-000343
Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome
Prashant Pandya, Chaitanya Pant, Ryan Taylor, Olurinde Oni
Journal of Investigative Medicine Apr 2017, 65 (4) 765-771; DOI: 10.1136/jim-2016-000343
Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome
Prashant Pandya, Chaitanya Pant, Ryan Taylor, Olurinde Oni
Journal of Investigative Medicine Apr 2017, 65 (4) 765-771; DOI: 10.1136/jim-2016-000343